Rhythm patent expiration

1. Imcivree patent expiration

IMCIVREE's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9458195 RHYTHM Melanocortin receptor ligands
Oct, 2027

(3 years from now)

US8039435 RHYTHM Melanocortin receptor ligands
Oct, 2027

(3 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11129869 RHYTHM Pharmaceutical compositions
Jul, 2034

(9 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-892) Jun 16, 2025
New Chemical Entity Exclusivity(NCE) Nov 25, 2025
Orphan Drug Exclusivity(ODE-336) Nov 25, 2027
Orphan Drug Exclusivity(ODE-402) Jun 16, 2029

Drugs and Companies using SETMELANOTIDE ACETATE ingredient

NCE-1 date: 25 November, 2024

Market Authorisation Date: 25 November, 2020

Treatment: NA

Dosage: SOLUTION

More Information on Dosage

IMCIVREE family patents

Family Patents